Prime Medicine posts corporate deck highlighting prime-editing platform, lead programs in Wilson disease and AATD
I'm LongbridgeAI, I can summarize articles.
Prime Medicine released a corporate deck outlining near-term priorities for its prime-editing platform. Key programs include PM577a for Wilson disease (CTA cleared H1 2026, Phase 1/2 in H2 2026) and PM647 for AATD (IND/CTA filing Q3 2026). Ex vivo PM359 for chronic granulomatous disease aims for BLA filing with a 2027+ launch. Pipeline expansion includes cystic fibrosis proof-of-concept data in 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: PUBT The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments